JP2016515508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515508A5 JP2016515508A5 JP2016502111A JP2016502111A JP2016515508A5 JP 2016515508 A5 JP2016515508 A5 JP 2016515508A5 JP 2016502111 A JP2016502111 A JP 2016502111A JP 2016502111 A JP2016502111 A JP 2016502111A JP 2016515508 A5 JP2016515508 A5 JP 2016515508A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- protein
- fusion
- septin
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims description 139
- 230000004927 fusion Effects 0.000 claims description 121
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 98
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 98
- 108020001507 fusion proteins Proteins 0.000 claims description 91
- 102000037865 fusion proteins Human genes 0.000 claims description 91
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 85
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 230000003321 amplification Effects 0.000 claims description 20
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 17
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 102100038607 Cullin-associated NEDD8-dissociated protein 1 Human genes 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- 101000741329 Homo sapiens Cullin-associated NEDD8-dissociated protein 1 Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000010195 expression analysis Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 238000001155 isoelectric focusing Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 102000015602 Septin Human genes 0.000 claims 10
- 108050004875 Septin Proteins 0.000 claims 10
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 7
- 102100021762 Phosphoserine phosphatase Human genes 0.000 claims 7
- 108010076573 phosphoserine phosphatase Proteins 0.000 claims 7
- 102100027062 Septin-14 Human genes 0.000 claims 3
- 101710005685 Septin-14 Proteins 0.000 claims 3
- 102100024382 Cullin-associated NEDD8-dissociated protein 2 Human genes 0.000 claims 1
- 101000910263 Homo sapiens Cullin-associated NEDD8-dissociated protein 2 Proteins 0.000 claims 1
- 101100516912 Homo sapiens NPAT gene Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100038870 Protein NPAT Human genes 0.000 claims 1
- 102000017500 Septin 2 Human genes 0.000 claims 1
- 108050005721 Septin 2 Proteins 0.000 claims 1
- 102000004275 Septin 3 Human genes 0.000 claims 1
- 108090000881 Septin 3 Proteins 0.000 claims 1
- 102000012066 Septin 5 Human genes 0.000 claims 1
- 108050002582 Septin 5 Proteins 0.000 claims 1
- 102000012061 Septin 6 Human genes 0.000 claims 1
- 108050002583 Septin 6 Proteins 0.000 claims 1
- 102000017496 Septin 7 Human genes 0.000 claims 1
- 108050005730 Septin 7 Proteins 0.000 claims 1
- 102000044463 Septin 8 Human genes 0.000 claims 1
- 108700036698 Septin 8 Proteins 0.000 claims 1
- 102000012060 Septin 9 Human genes 0.000 claims 1
- 108050002584 Septin 9 Proteins 0.000 claims 1
- 102100027698 Septin-1 Human genes 0.000 claims 1
- 101710026668 Septin-1 Proteins 0.000 claims 1
- 102100031402 Septin-10 Human genes 0.000 claims 1
- 101710005687 Septin-10 Proteins 0.000 claims 1
- 102100027068 Septin-11 Human genes 0.000 claims 1
- 101710005686 Septin-11 Proteins 0.000 claims 1
- 102100032743 Septin-4 Human genes 0.000 claims 1
- 101710127283 Septin-4 Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 description 18
- 101710138656 Leucine-zipper-like transcriptional regulator 1 Proteins 0.000 description 12
- 102100040274 Leucine-zipper-like transcriptional regulator 1 Human genes 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000012049 whole transcriptome sequencing Methods 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 5
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 5
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 101150113466 cul-3 gene Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 101001023793 Homo sapiens Neurofascin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100035414 Neurofascin Human genes 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 102000008836 BTB/POZ domains Human genes 0.000 description 2
- 108050000749 BTB/POZ domains Proteins 0.000 description 2
- 102100037410 Gigaxonin Human genes 0.000 description 2
- 108050003250 Gigaxonin Proteins 0.000 description 2
- 101001091348 Homo sapiens Kelch-like protein 11 Proteins 0.000 description 2
- 101001045824 Homo sapiens Kelch-like protein 3 Proteins 0.000 description 2
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102100034875 Kelch-like protein 11 Human genes 0.000 description 2
- 102100022101 Kelch-like protein 3 Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102100036422 Speckle-type POZ protein Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- 241000568526 Amphimedon queenslandica Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 1
- 241001440732 Capsaspora owczarzaki Species 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001622440 Monosiga Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000662257 Salpingoeca rosetta Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793086P | 2013-03-15 | 2013-03-15 | |
| US61/793,086 | 2013-03-15 | ||
| PCT/US2014/026351 WO2014151734A1 (en) | 2013-03-15 | 2014-03-13 | Fusion proteins and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515508A JP2016515508A (ja) | 2016-05-30 |
| JP2016515508A5 true JP2016515508A5 (enExample) | 2017-04-13 |
Family
ID=51581025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502111A Pending JP2016515508A (ja) | 2013-03-15 | 2014-03-13 | 融合タンパク質及びその方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10208296B2 (enExample) |
| EP (1) | EP2968551B1 (enExample) |
| JP (1) | JP2016515508A (enExample) |
| KR (1) | KR20150129847A (enExample) |
| AU (1) | AU2014236947A1 (enExample) |
| CA (1) | CA2907152A1 (enExample) |
| WO (1) | WO2014151734A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| EP3925979A3 (en) * | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018112090A1 (en) | 2016-12-13 | 2018-06-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating cancers containing fusion genes |
| AU2017258901A1 (en) * | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US11608533B1 (en) * | 2017-08-21 | 2023-03-21 | The General Hospital Corporation | Compositions and methods for classifying tumors with microsatellite instability |
| US11110177B2 (en) * | 2017-11-10 | 2021-09-07 | The Regents Of The University Of Michigan | ASH1L degraders and methods of treatment therewith |
| CN109810184B (zh) * | 2019-01-17 | 2022-07-12 | 武汉明德生物科技股份有限公司 | 人nf155抗原、人nf155抗体检测试剂盒及其制备方法与应用 |
| WO2021041324A2 (en) * | 2019-08-23 | 2021-03-04 | Duke University | Compositions and methods for the treatment of pathological pain and itch |
| KR102277471B1 (ko) * | 2019-10-22 | 2021-07-14 | 주식회사 지니스 | '혈관내 혈전' 용해제 |
| KR102362115B1 (ko) * | 2019-10-22 | 2022-02-14 | 주식회사 지니스 | '혈관내 혈전' 용해제 |
| US20230295734A1 (en) * | 2020-03-04 | 2023-09-21 | Foundation Medicine, Inc. | Bcor rearrangements and uses thereof |
| WO2024064679A1 (en) * | 2022-09-20 | 2024-03-28 | Foundation Medicine, Inc. | Methods and systems for functional status assignment of genomic variants |
| CN115312119B (zh) * | 2022-10-09 | 2023-04-07 | 之江实验室 | 基于蛋白质三维结构图像鉴定蛋白质结构域的方法及系统 |
| WO2024103032A2 (en) * | 2022-11-11 | 2024-05-16 | The Trustees Of Columbia University In The City Of New York | Lztr1 mutant tumors and methods thereof |
| WO2025019568A1 (en) * | 2023-07-17 | 2025-01-23 | The Penn State Research Foundation | Improving immune cell-based therapies against solid tumors with optogenetically engineered septin proteins |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| ATE107176T1 (de) | 1989-12-04 | 1994-07-15 | Searle & Co | System zur transdermalen albuterol applikation. |
| US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
| WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| SK70598A3 (en) | 1995-11-30 | 1999-04-13 | Univ Texas | Methods and compositions for the diagnosis and treatment of cancer |
| US7419661B2 (en) | 1997-04-30 | 2008-09-02 | The Centre Of Excellence For Life Sciences Limited | Dermal sheath tissue in wound healing |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999035159A1 (en) * | 1998-01-08 | 1999-07-15 | Brigham & Women's Hospital, Inc. | Lymphoma/leukemia oncogene, oncoprotein and methods of use |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9925964D0 (en) | 1999-11-03 | 1999-12-29 | Jahoda Colin A B | Hair transplantation |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| KR20080051113A (ko) | 2005-05-02 | 2008-06-10 | 콜드스프링하버러보러토리 | Ｍｉｒ 17-92 클러스터를 이용한 암 진단용 조성물 및 방법 |
| CN101336237B (zh) | 2005-12-21 | 2015-09-30 | 诺华股份有限公司 | 作为fgf抑制剂的嘧啶基芳基脲衍生物 |
| SI2068880T1 (sl) * | 2006-09-18 | 2012-08-31 | Boehringer Ingelheim Int | Postopek za zdravljenje raka, ki vsebuje mutacije EGFR |
| US8242080B2 (en) * | 2006-10-13 | 2012-08-14 | The Regents Of The University Of California | Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| EP2170062A4 (en) | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
| US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
| AR078411A1 (es) | 2009-05-07 | 2011-11-09 | Lilly Co Eli | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
| AU2013295805B2 (en) | 2012-07-24 | 2019-05-02 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| EP3925979A3 (en) | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
-
2014
- 2014-03-13 EP EP14769771.8A patent/EP2968551B1/en active Active
- 2014-03-13 JP JP2016502111A patent/JP2016515508A/ja active Pending
- 2014-03-13 AU AU2014236947A patent/AU2014236947A1/en not_active Abandoned
- 2014-03-13 KR KR1020157029166A patent/KR20150129847A/ko not_active Withdrawn
- 2014-03-13 WO PCT/US2014/026351 patent/WO2014151734A1/en not_active Ceased
- 2014-03-13 CA CA2907152A patent/CA2907152A1/en not_active Abandoned
-
2015
- 2015-09-14 US US14/853,568 patent/US10208296B2/en active Active
-
2019
- 2019-01-11 US US16/246,167 patent/US11505788B2/en active Active
-
2022
- 2022-10-12 US US18/046,131 patent/US20230303985A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515508A5 (enExample) | ||
| Singh et al. | Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody | |
| KR101621643B1 (ko) | 다중 pcr 반응에서 증폭 바이어스를 측정 및 교정하기 위한 조성물 및 방법 | |
| Bashirova et al. | Population-specific diversity of the immunoglobulin constant heavy G chain (IGHG) genes | |
| EP3802922B1 (en) | Novel immune checkpoint inhibitors | |
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| US10175244B2 (en) | Dominant negative HSP110 mutant and its use in prognosing and treating cancers | |
| Hanke et al. | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies | |
| CN104619841A (zh) | Cep55基因与ret基因的融合基因 | |
| EP2348135A2 (de) | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie | |
| KR20230140553A (ko) | Tl1a를 표적으로 하는 염증성 질환의 치료를 위한 방법, 시스템, 및 키트 | |
| JP2009039107A5 (enExample) | ||
| US20230105008A1 (en) | Methods and compositions for identifying castration resistant neuroendocrine prostate cancer | |
| US20200141947A1 (en) | Compositions and methods for treating age-related diabetes and related disorders | |
| CN107922975A (zh) | 治疗眼科病症的方法 | |
| WO1999028459A1 (fr) | Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1 | |
| Oh et al. | Development of an anti-canine PD-L1 antibody and caninized PD-L1 mouse model as translational research tools for the study of immunotherapy in humans | |
| Niktoreh et al. | Understanding WT1 alterations and expression profiles in hematological malignancies | |
| CN114729403A (zh) | 用于鉴定和验证共有候选抗原和共有抗原特异性t淋巴细胞对的方法和系统 | |
| WO2018181863A1 (ja) | 異なる複数の目的遺伝子の評価方法 | |
| Sidiropoulos et al. | Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironment | |
| Ross et al. | A mutation in mouse Pak1ip1 causes orofacial clefting while human PAK1IP1 maps to 6p24 translocation breaking points associated with orofacial clefting | |
| EP1399584A2 (en) | Cancer-linked genes as targets for chemotherapy | |
| Wen et al. | Identification and characterization of IgNAR and VNAR repertoire from the ocellate spot skate (Okamejei kenojei) | |
| CN104650214B (zh) | 肺动脉高压致病基因acvrl1突变位点及其应用 |